Trial intelligence / Profile preview

Vinflunine combinations in cisplatin-ineligible advanced urothelial carcinoma

2010-020620-22Phase 2Completed

Sponsor: Pierre Fabre Laboratories
Start: Oct 2010
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised trial in transitional cell carcinoma (TCC) comparing Vinflunine + gemcitabine with Vinflunine + carboplatin (2 arms). Primary endpoint: Disease control rate. Started Oct 2010; status: completed.

Drugs

vinfluninegemcitabinecarboplatin

Conditions

transitional cell carcinoma (TCC)

Beyond the preview

Go deeper on 2010-020620-22.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-020620-22.